ADARx Pharmaceuticals, Inc., located in San Diego, is a clinical stage biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx has developed proprietary RNA targeting platforms and oligonucleotide delivery technologies for inhibition, degradation, and editing disease-causing mRNA. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated diseases and central nervous system diseases. We are well-financed by a syndicate of renowned VC firms. ADARx currently has multiple active programs in development. Our lead candidate is at the clinical stage. Show more Show less
$200M sweet spot round size
2019
$200M
from 3 investors over 1 rounds
ADARx Pharmaceuticals Inc. raised $200M on September 9, 2023
Investors: TCG Crossover, Bain Capital Life Sciences and + 14 Other investors